Cipla was established in 1935 with the vision of making India self-reliant and self-sufficient in healthcare. Today, we are one of the world’s largest generic pharmaceutical companies with a presence in over 170 countries. We are renowned for making affordable, world-class medicines that meet the needs of patients across therapies. We also offer services like consulting, commissioning, plant engineering, technical know-how transfer and support.
Cipla Ltd., Mumbai Central, Mumbai 400 008, India
Chairman and MD
Dr. Yusuf K. Hamied
Joint Managing Director
Mr. M.K. Hamied
BSE Limited, National Stock Exchange (NSE), Luxembourg Stock Exchange
USD 1.4 billion
US FDA, WHO-Geneva, MHRA-UK, TGA-Australia, SUKL-Slovak Republic, APVMA-Australia, MCC-South Africa, PIC-Germany, Danish Medical Agency, ANVISA-Brazil, INVIMA- Colombia, NDA-Uganda, Department of Health-Canada and MOH-Saudi Arabia, among others
One of the world’s largest generic companies.
Over 2,000 products, 65 therapeutic categories, over 40 dosage forms.
34 state-of-the-art manufacturing facilities approved by major international regulatory agencies.
Continuous innovation in R&D; over 20 world firsts.
+91 22 23082891, +91 22 23095521